{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
benzyl alcohol
to a specific field?
Status:
Other
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Conditions:
RO 15-4513 is a high-affinity benzodiazepine ligand which acts as a partial inverse agonist at recombinant diazepam-sensitive (DS) benzodiazepine α1-, α2-, α3- and α5-GABAA receptors, developed by Hoffmann–La Roche in the 1980s. Ro 15-4513 reverses the sedating and anticonflict effects of alcohol, and can, therefore, be used as an antidote to the acute impairment caused by alcohol. In non-food or fluid-deprived rats, orally self-administering 10% alcohol in an operant situation, Ro 15-4513 resulted in a dose-dependent suppression of alcohol intake. The use of Ro 15-4513 would appear to be limited by the fact that the compound is proconvulsant. Ro 15-4513 has been found to induce seizures in mice undergoing ethanol withdrawal. However, it is a potentially powerful tool with which to investigate the neuropsychopharmacology of alcohol. Labelling Ro15-4513 with carbon-11 leads to the possibility of its use in PET imaging of the brain. The specificity of the compound to a small number of GABA receptor sub-types leads to the generation, with accurate modeling, of detailed images with well-defined limbic and cortical structures. These images can be useful in quantitatively analyzing conditions such as addiction, that is known to be, at least in part, associated with the GABAergic system.
